厦门金达威集团股份有限公司 2015 年半年度报告全文 厦门金达威集团股份有限公司 2015 年半年度报告 2015 年 08 月 1 厦门金达威集团股份有限公司 2015 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本报告的董事会会议。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 公司负责人江斌、主管会计工作负责人马国清及会计机构负责人(会计主管 人员)黄宏芸声明：保证本半年度报告中财务报告的真实、准确、完整。 2 | 目录 | | --- | | 第一节 | 重要提示、目录和释义 5 | | --- | --- | | 第二节 | 公司简介 7 | | 第三节 | 会计数据和财务指标摘要 9 | | 第四节 | 董事会报告 23 | | 第五节 | 重要事项 34 | | 第六节 | 股份变动及股东情况 37 | | 第七节 | 优先股相关情况 37 | | 第八节 | 董事、监事、高级管理人员情况 38 | | 第 ...

厦门金达威集团股份有限公司 2015 年第一季度报告正文 证券代码：002626 证券简称：金达威 公告编号：2015-036 厦门金达威集团股份有限公司 2015 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误导性 陈述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 253,433,743.13 | 193,096,099.73 | 31.25% | | 归属于上市公司股东的净利润（元） | 41,531,730.50 | 44,339,200.20 | -6.33% | | 归属于上市公司股东的扣除非经常性损 益的净利润（元） | 40,640,057.05 | 44,161,190.73 | ...

厦门金达威集团股份有限公司 2014 年年度报告全文 厦门金达威集团股份有限公司 2014 年年度报告 2015 年 03 月 1 厦门金达威集团股份有限公司 2014 年年度报告全文 第一节 重要提示、目录和释义 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本报告的董事会会议。 公司经本次董事会审议通过的利润分配预案为：以 2014 年 12 月 31 日的公 司总股本为基数，向全体股东每 10 股派发现金红利 3.00 元（含税），送红股 0 股（含税），以资本公积金向全体股东每 10 股转增 10 股。 公司负责人江斌、主管会计工作负责人马国清及会计机构负责人(会计主管 人员)黄宏芸声明：保证年度报告中财务报告的真实、准确、完整。 2 | 目录 | | --- | | 2014 | 年度报告 2 | | --- | --- | | 第一节 | 重要提示、目录和释义 7 | | 第二节 | 公司简介 9 | | 第三节 | 会计数据和财务指标摘要 11 | | 第四节 | 董 ...

[Important Notice](index=1&type=section&id=Section%20I.%20Important%20Notice) The company's management ensures the accuracy and completeness of this quarterly report, with all directors participating in its review - The company's board of directors, supervisory board, and all senior management ensure the truthfulness, accuracy, and completeness of this quarterly report and bear corresponding legal responsibilities; all directors attended the board meeting to review this quarterly report[2](index=2&type=chunk) [Key Financial Data and Shareholder Changes](index=1&type=section&id=Section%20II.%20Key%20Financial%20Data%20and%20Shareholder%20Changes) This section presents the company's key financial performance indicators and details of its shareholder structure during the reporting period [Key Accounting Data and Financial Indicators](index=1&type=section&id=I.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) The company achieved high growth in the first three quarters of 2014, with operating revenue increasing by 23.51% and net profit attributable to shareholders of the listed company significantly growing by 125.72% 2014 First Three Quarters Key Financial Indicators | Indicator | Year-to-Date | Year-to-Date Change from Prior Year (%) | | :--- | :--- | :--- | | Operating Revenue (RMB) | 592,254,122.41 | 23.51% | | Net Profit Attributable to Shareholders of the Listed Company (RMB) | 147,159,696.28 | 125.72% | | Net Profit Attributable to Shareholders of the Listed Company After Deducting Non-Recurring Gains and Losses (RMB) | 143,514,991.80 | 138.01% | | Net Cash Flow from Operating Activities (RMB) | 103,189,735.89 | -21.91% | | Basic Earnings Per Share (RMB/share) | 0.51 | 121.74% | 2014 First Three Quarters Non-Recurring Gains and Losses Items | Item | Year-to-Date Amount (RMB) | | :--- | :--- | | Gains/Losses from Disposal of Non-Current Assets | -155,179.49 | | Government Subsidies Included in Current Profit/Loss | 3,678,470.29 | | Other Non-Operating Income and Expenses | 764,803.28 | | Less: Income Tax Impact | 643,389.60 | | **Total** | **3,644,704.48** | [Shareholder Information](index=2&type=section&id=II.%20Total%20Number%20of%20Shareholders%20and%20Shareholding%20of%20Top%20Ten%20Shareholders%20at%20the%20End%20of%20the%20Reporting%20Period) As of the end of the reporting period, the company had 11,457 common shareholders, with a relatively concentrated equity structure dominated by the top two shareholders - As of the end of the reporting period, the company had **11,457** common shareholders[8](index=8&type=chunk) Top Three Shareholders' Shareholding | Shareholder Name | Shareholder Nature | Shareholding Ratio | Number of Shares | Pledged or Frozen Status | | :--- | :--- | :--- | :--- | :--- | | Xiamen Kingdawei Investment Co., Ltd. | Domestic Non-State-Owned Legal Person | 35.00% | 100,805,286 | Pledged 70,000,000 | | China Animal Husbandry Industry Co., Ltd. | State-Owned Legal Person | 26.47% | 76,230,592 | None | | Xiamen Special Economic Zone Development Co., Ltd. | State-Owned Legal Person | 6.24% | 17,963,693 | Pledged 17,952,000 | [Significant Matters](index=4&type=section&id=Section%20III.%20Significant%20Matters) This section details significant events, financial item changes, shareholder commitments, and future performance forecasts [Analysis of Major Financial Item Changes](index=4&type=section&id=I.%20Changes%20and%20Reasons%20for%20Major%20Accounting%20Statement%20Items%20and%20Financial%20Indicators%20in%20the%20Reporting%20Period) During the reporting period, several financial indicators changed significantly, driven by increased vitamin A prices and improved Coenzyme Q10 product performance, alongside asset reclassifications and business expansion - Operating profit and net profit significantly increased year-on-year, primarily due to rising **Vitamin A prices** and decreasing costs with increasing sales of **Coenzyme Q10 products**[12](index=12&type=chunk) - **Fixed Assets**: Increased by **51.69%** from the beginning of the year, mainly due to the completion and transfer of Coenzyme Q10 expansion projects[12](index=12&type=chunk) - **Construction in Progress**: Decreased by **88.33%** from the beginning of the year, for the same reasons as fixed assets[12](index=12&type=chunk) - **Prepayments**: Increased by **130.76%** from the beginning of the year, mainly due to increased prepayments for projects[12](index=12&type=chunk) - **Inventories**: Increased by **56.01%** from the beginning of the year, due to increased finished goods and raw material inventory[12](index=12&type=chunk) - **Financial Expenses**: Decreased by **105.98%** year-on-year, primarily due to a decrease in exchange losses[12](index=12&type=chunk) [Progress of Significant Matters](index=5&type=section&id=II.%20Analysis%20and%20Explanation%20of%20the%20Progress%20of%20Significant%20Matters%20and%20Their%20Impact%20and%20Solutions) The company is planning a significant matter with uncertainty, leading to a trading suspension of its shares since October 9, 2014, with regular progress announcements - The company's shares have been suspended from trading since **October 9, 2014**, due to planning a significant matter, which remains uncertain as of the report disclosure date[13](index=13&type=chunk)[14](index=14&type=chunk) [Shareholder Commitments and Fulfillment](index=5&type=section&id=III.%20Commitments%20Made%20by%20the%20Company%20or%20Shareholders%20Holding%205%25%20or%20More%20Shares%20During%20or%20Continuing%20into%20the%20Reporting%20Period) During the reporting period, the company and its major shareholders strictly fulfilled all commitments made, including share lock-ups, avoiding horizontal competition, and maintaining company independence - The controlling shareholder and actual controller strictly fulfilled commitments regarding **share lock-up**, litigation compensation, **avoidance of horizontal competition**, and non-occupation of company funds[15](index=15&type=chunk)[16](index=16&type=chunk) - The company fulfilled its commitment regarding **cash dividends** as per the "Company's Shareholder Return Plan for the Next Three Years (2012-2014)"[16](index=16&type=chunk) [2014 Annual Performance Forecast](index=7&type=section&id=IV.%20Forecast%20of%202014%20Annual%20Operating%20Performance) The company forecasts a significant increase in full-year net profit for 2014, driven by increased sales of Coenzyme Q10 and higher Vitamin A prices 2014 Annual Performance Forecast | Item | Forecast Situation | | :--- | :--- | | Net Profit Attributable to Parent Company Change Range | 65.00% to 115.00% | | Net Profit Attributable to Parent Company Change Range (RMB 10,000) | 16,851.55 to 21,958.08 | | 2013 Net Profit Attributable to Parent Company (RMB 10,213.06) | | - The main reasons for the forecast increase are: **1. Increased sales of Coenzyme Q10 products; 2. Higher Vitamin A prices** compared to the same period last year[17](index=17&type=chunk) [Securities Investment Status](index=7&type=section&id=V.%20Securities%20Investment%20Status) During the reporting period, the company did not engage in any securities investments or hold equity in other listed companies - The company had **no securities investments** or holdings in other listed companies during the reporting period[18](index=18&type=chunk) [Impact of New Accounting Standards](index=7&type=section&id=VI.%20Impact%20of%20Newly%20Issued%20or%20Revised%20Accounting%20Standards%20on%20the%20Company's%20Consolidated%20Financial%20Statements) Newly issued or revised accounting standards had no impact on the company's consolidated financial statements during the reporting period - The company's financial statements were **not impacted** by newly issued or revised accounting standards[19](index=19&type=chunk)

[Important Notes, Table of Contents, and Definitions](index=2&type=section&id=Section%201%20Important%20Notes%2C%20Table%20of%20Contents%2C%20and%20Definitions) [Important Notes and Definitions](index=2&type=section&id=1.1%20Important%20Notes%20and%20Definitions) This section contains the board's guarantee of the report's authenticity, the plan for no profit distribution for H1 2014, and definitions of key terms - The Board of Directors, Board of Supervisors, and all senior executives guarantee the authenticity, accuracy, and completeness of this semi-annual report and assume corresponding legal responsibilities[3](index=3&type=chunk) - The company's profit distribution plan for the first half of 2014 is **no cash dividends, no bonus shares, and no capitalization of public reserve funds**[5](index=5&type=chunk) - The report provides definitions for core products and projects, including Coenzyme Q10 (a metabolic activator and antioxidant), DHA (essential for brain and visual function), ARA (an essential unsaturated fatty acid), Vitamin A, and Vitamin D3[10](index=10&type=chunk) [Company Profile](index=5&type=section&id=Section%202%20Company%20Profile) [Basic Company Information](index=5&type=section&id=2.1%20Basic%20Company%20Information) This section provides basic corporate information, noting that while contact details remained unchanged, the company completed its business registration amendment during the period Company Profile | Item | Content | | :--- | :--- | | Stock Ticker | Kingdomway | | Stock Code | 002626 | | Stock Exchange | Shenzhen Stock Exchange | | Full Company Name (Chinese) | 厦门金达威集团股份有限公司 | | Legal Representative | Jiang Bin | - During the reporting period, the company completed its business registration amendment on **May 7, 2014**, with no changes to information disclosure channels or contact details[15](index=15&type=chunk)[16](index=16&type=chunk)[17](index=17&type=chunk) [Financial Highlights](index=7&type=section&id=Section%203%20Summary%20of%20Accounting%20Data%20and%20Financial%20Indicators) [Key Accounting Data and Financial Indicators](index=7&type=section&id=3.1%20Key%20Accounting%20Data%20and%20Financial%20Indicators) The company achieved strong performance in H1 2014, with revenue up 28.43% and net profit attributable to shareholders surging 180.01%, though operating cash flow declined Key Financial Indicators for H1 2014 | Indicator | Current Period | Prior Year Period | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue (RMB) | 402,551,919.16 | 313,439,235.24 | 28.43% | | Net Profit Attributable to Shareholders (RMB) | 101,907,634.65 | 36,394,237.32 | 180.01% | | Net Cash Flow from Operating Activities (RMB) | 65,789,379.59 | 87,331,448.39 | -24.67% | | Basic Earnings Per Share (RMB/Share) | 0.35 | 0.13 | 169.23% | | Weighted Average Return on Equity | 7.45% | 2.85% | 4.60% | | Total Assets (RMB) | 1,441,396,329.43 | 1,409,323,255.53 | 2.28% (vs. Year-End) | | Net Assets Attributable to Shareholders (RMB) | 1,329,187,833.80 | 1,317,280,199.15 | 0.90% (vs. Year-End) | - Non-recurring gains and losses for the period totaled **RMB 1,999,102.20**, primarily from government subsidies[25](index=25&type=chunk) [Board of Directors' Report](index=9&type=section&id=Section%204%20Board%20of%20Directors'%20Report) [Business Overview](index=9&type=section&id=4.1%20Business%20Overview) The company's operations showed healthy growth, with revenue reaching RMB 403 million and net profit surging 180.01%, driven by key product sales and project progress - The significant performance improvement was mainly driven by: - Increased sales volume and reduced costs for the main product, **Coenzyme Q10** - Higher sales prices for **Vitamin A** due to tight market supply[29](index=29&type=chunk) - Key company projects are progressing smoothly: - Construction of the health food softgel production line is on track - The subsidiary's 60-ton/year Coenzyme Q10 expansion project in Inner Mongolia is complete and will soon be operational[28](index=28&type=chunk) [Analysis of Main Business Operations](index=9&type=section&id=4.2%20Analysis%20of%20Main%20Business%20Operations) The main business demonstrated strong performance, with the industrial segment's gross margin increasing by 10.80 percentage points, driven by significant growth in export sales Main Business Composition (by Product) | Product | Operating Revenue (RMB) | Gross Margin | Revenue YoY Change | Gross Margin YoY Change | | :--- | :--- | :--- | :--- | :--- | | Coenzyme Q10 Series | 229,690,030.79 | 43.90% | 46.64% | 5.18% | | Vitamin A Series | 140,603,179.41 | 48.48% | 24.70% | 13.88% | | Others | 31,564,760.58 | 11.32% | -26.85% | 9.50% | Main Business Composition (by Region) | Region | Operating Revenue (RMB) | Gross Margin | Revenue YoY Change | Gross Margin YoY Change | | :--- | :--- | :--- | :--- | :--- | | Export Sales | 299,564,950.50 | 40.98% | 45.55% | 9.06% | | Domestic Sales | 102,293,020.28 | 48.70% | -4.16% | 16.13% | - **Financial expenses decreased by 160.79%** year-on-year, mainly due to a RMB 6.3167 million reduction in exchange losses, while net cash flow from investing activities increased by **139.28%** due to the recovery of bank wealth management products and reduced capital expenditures[30](index=30&type=chunk) [Investment Analysis](index=10&type=section&id=4.3%20Investment%20Analysis) The company invested RMB 9 million to establish a trading subsidiary, utilized RMB 570 million in idle funds for wealth management, and reported strong performance from its main subsidiary - An external investment of **RMB 9 million** was made to establish the wholly-owned subsidiary 'Xiamen Xindewei International Trade Co, Ltd' for import and export trade[35](index=35&type=chunk)[36](index=36&type=chunk) - The company used idle raised funds and its own capital for wealth management, with a cumulative amount of **RMB 570 million**, generating a profit of **RMB 5.6414 million** during the period[41](index=41&type=chunk) Operating Performance of Major Subsidiaries | Company Name | Net Assets (RMB) | Operating Revenue (RMB) | Net Profit (RMB) | | :--- | :--- | :--- | :--- | | Inner Mongolia Kingdomway Pharmaceutical Co, Ltd | 537,372,101.38 | 219,255,039.67 | 59,313,981.16 | [Performance Forecast and Profit Distribution](index=13&type=section&id=4.4%20Performance%20Forecast%20and%20Profit%20Distribution) The company forecasts 100%-150% net profit growth for the first three quarters of 2014, completed its 2013 profit distribution, and plans no distribution for the first half of 2014 - The company forecasts that net profit attributable to parent company shareholders for the first three quarters of 2014 will increase by **100% to 150%**, reaching between **RMB 130 million and RMB 163 million**[49](index=49&type=chunk) - The 2013 profit distribution plan (a cash dividend of RMB 5 and 6 bonus shares for every 10 shares) was fully implemented on **June 6, 2014**[51](index=51&type=chunk) - The company plans **no cash dividends, no bonus shares, and no capitalization of public reserve funds** for the first half of 2014[53](index=53&type=chunk) [Significant Events](index=16&type=section&id=Section%205%20Significant%20Events) [Major Litigation and Related-Party Transactions](index=16&type=section&id=5.1%20Major%20Litigation%20and%20Related-Party%20Transactions) The company received a favorable ruling in its patent lawsuit with Kaneka Corporation, which is now under appeal, and conducted routine related-party sales within approved limits - Regarding the Coenzyme Q10 patent litigation with Kaneka Corporation of Japan, the U.S. District Court for the Central District of California issued a favorable judgment on **March 27, 2014**, permanently dismissing all of Kaneka's claims; Kaneka has since filed an appeal[59](index=59&type=chunk) - During the period, the company's sales of vitamin products to shareholder China Animal Husbandry Industry Co, Ltd amounted to **RMB 10.5254 million**, accounting for 6.36% of similar transactions and remaining within the annual forecast[66](index=66&type=chunk)[67](index=67&type=chunk) [Commitments](index=19&type=section&id=5.2%20Commitments) The controlling shareholder and actual controller strictly adhered to their lock-up commitments, while long-term commitments regarding competition and dividends were also fulfilled - The controlling shareholder, Xiamen Kingdomway Investment Co, Ltd, and the actual controller, Mr. Jiang Bin, strictly fulfilled their **36-month share lock-up commitment** from the IPO date, with no violations during the reporting period[79](index=79&type=chunk) - The controlling shareholder and actual controller continued to fulfill long-term commitments regarding the **avoidance of horizontal competition, maintenance of company independence, and non-occupation of company funds**[80](index=80&type=chunk) - The company fulfilled its commitment under the 'Shareholder Return Plan for the Next Three Years (2012-2014)' to pay an annual cash dividend of **no less than 10% of the distributable profit** for the year[80](index=80&type=chunk)[81](index=81&type=chunk) [Changes in Share Capital and Shareholders](index=22&type=section&id=Section%206%20Changes%20in%20Share%20Capital%20and%20Shareholders) [Changes in Share Capital](index=22&type=section&id=6.1%20Changes%20in%20Share%20Capital) The company's total share capital increased from 180 million to 288 million shares due to the implementation of the 2013 profit distribution plan involving a bonus issue Changes in Share Capital | Share Class | Pre-Change Quantity | Change (Bonus Issue) | Post-Change Quantity | | :--- | :--- | :--- | :--- | | I. Restricted Shares | 63,787,142 | +38,272,285 | 102,059,427 | | II. Unrestricted Shares | 116,212,858 | +69,727,715 | 185,940,573 | | III. Total Shares | 180,000,000 | +108,000,000 | 288,000,000 | - The increase in total shares resulted from the implementation of the 2013 profit distribution plan, which involved a bonus issue of **6 shares for every 10 shares** from the capital reserve, completed on June 6, 2014[87](index=87&type=chunk) [Shareholder Information](index=23&type=section&id=6.2%20Shareholder%20Information) As of the period end, the company had 9,087 shareholders, with the top three holding a combined 67.71%, and a significant portion of the largest shareholder's stake was pledged - At the end of the reporting period, the total number of common shareholders was **9,087**[91](index=91&type=chunk) Top Three Shareholders | Shareholder Name | Shareholding Ratio | Shares Held at Period-End | Share Status | | :--- | :--- | :--- | :--- | | Xiamen Kingdomway Investment Co, Ltd | 35.00% | 100,805,286 | Pledged 100,800,000 | | China Animal Husbandry Industry Co, Ltd | 26.47% | 76,230,592 | - | | Xiamen Special Engineering Development Co, Ltd | 6.24% | 17,963,693 | Pledged 17,952,000 | - There were **no changes** in the company's controlling shareholder or actual controller during the reporting period[93](index=93&type=chunk) [Information on Preferred Shares](index=25&type=section&id=Section%207%20Information%20on%20Preferred%20Shares) [Preferred Share Status](index=25&type=section&id=7.1%20Preferred%20Share%20Status) The company had no issuance, listing, repurchase, or conversion of preferred shares during the reporting period - The company had **no issuance, listing, shareholder details, repurchase, or conversion of preferred shares** during the reporting period[95](index=95&type=chunk) [Directors, Supervisors, and Senior Management](index=26&type=section&id=Section%208%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) [Changes in Personnel](index=26&type=section&id=8.1%20Changes%20in%20Personnel) There were no changes in the shareholdings of directors, supervisors, or senior management, but Director Zhang Xingming resigned and was replaced by Gao Wei - There were **no changes** in the shareholdings of the company's directors, supervisors, and senior management during the reporting period[96](index=96&type=chunk) Changes in Directors and Senior Management | Name | Position | Type | Date | Reason | | :--- | :--- | :--- | :--- | :--- | | Zhang Xingming | Director, Vice Chairman | Resigned | 2014-02-19 | Personal work reasons | | Gao Wei | Director | Elected | 2014-04-17 | — | | Gao Wei | Vice Chairman | Elected | 2014-04-28 | — | [Financial Report](index=27&type=section&id=Section%209%20Financial%20Report) [Financial Statements](index=27&type=section&id=9.1%20Financial%20Statements) This section presents the unaudited H1 2014 consolidated and parent company financial statements, reflecting the company's financial position, performance, and cash flows - The company's semi-annual financial report for 2014 is **unaudited**[100](index=100&type=chunk) [Consolidated Balance Sheet](index=27&type=section&id=9.1.1%20Consolidated%20Balance%20Sheet) As of June 30, 2014, total assets were RMB 1.441 billion, total liabilities were RMB 113 million, and equity attributable to the parent company was RMB 1.329 billion Key Items from the Consolidated Balance Sheet (2014-06-30) | Item | Closing Balance (RMB) | Opening Balance (RMB) | | :--- | :--- | :--- | | Total Current Assets | 895,629,171.36 | 856,929,511.02 | | Total Non-Current Assets | 545,767,158.07 | 552,393,744.51 | | **Total Assets** | **1,441,396,329.43** | **1,409,323,255.53** | | Total Current Liabilities | 92,684,303.27 | 84,156,644.83 | | Total Non-Current Liabilities | 20,032,833.33 | 8,108,333.33 | | **Total Liabilities** | **112,717,136.60** | **92,264,978.16** | | Total Equity Attributable to Parent Company | 1,329,187,833.80 | 1,317,280,199.15 | | **Total Equity** | **1,328,679,192.83** | **1,317,058,277.37** | [Consolidated Income Statement](index=32&type=section&id=9.1.2%20Consolidated%20Income%20Statement) In H1 2014, the company achieved total operating revenue of RMB 403 million and net profit attributable to the parent company of RMB 102 million, a 180.01% year-on-year increase Key Items from the Consolidated Income Statement (Jan-Jun 2014) | Item | Current Period Amount (RMB) | Prior Period Amount (RMB) | | :--- | :--- | :--- | | Total Operating Revenue | 402,551,919.16 | 313,439,235.24 | | Operating Profit | 117,133,957.54 | 41,668,697.74 | | Total Profit | 119,485,842.48 | 43,015,302.70 | | Net Profit | 101,620,915.46 | 36,394,237.32 | | Net Profit Attributable to Parent Company | 101,907,634.65 | 36,394,237.32 | [Consolidated Cash Flow Statement](index=34&type=section&id=9.1.3%20Consolidated%20Cash%20Flow%20Statement) Net operating cash flow was RMB 65.79 million, while net investing cash flow turned positive to RMB 34.34 million, and cash and equivalents ended at RMB 371 million Key Items from the Consolidated Cash Flow Statement (Jan-Jun 2014) | Item | Current Period Amount (RMB) | Prior Period Amount (RMB) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 65,789,379.59 | 87,331,448.39 | | Net Cash Flow from Investing Activities | 34,340,799.59 | -87,436,160.19 | | Net Cash Flow from Financing Activities | -84,386,346.00 | -54,000,000.00 | | Net Increase in Cash and Cash Equivalents | 18,029,296.18 | -58,135,916.30 | [Key Accounting Policies, Estimates, and Prior Period Errors](index=44&type=section&id=9.2%20Key%20Accounting%20Policies%2C%20Estimates%2C%20and%20Prior%20Period%20Errors) This section details the accounting standards and key policies applied, confirming no changes to policies or estimates and no prior period errors were identified - The company's financial statements are prepared on a **going concern basis** in accordance with China Accounting Standards for Business Enterprises (CAS)[137](index=137&type=chunk)[138](index=138&type=chunk) - Revenue is recognized when the main risks and rewards of ownership have been transferred to the buyer and the amounts can be reliably measured; domestic sales are confirmed upon customer receipt, while export sales are based on customs declarations[203](index=203&type=chunk) - During the reporting period, there were **no changes** in the company's key accounting policies or estimates, and no prior period accounting errors were identified[210](index=210&type=chunk)[211](index=211&type=chunk) [Taxation](index=59&type=section&id=9.3%20Taxation) The company is subject to a 17% VAT and a preferential 15% corporate income tax rate for both the parent company and its Inner Mongolia subsidiary due to specific qualifications - The parent company was recognized as a High-Tech Enterprise for 2011-2013 and is currently reapplying for this status, provisionally applying a **15% corporate income tax rate** for 2014[216](index=216&type=chunk) - The subsidiary, Inner Mongolia Kingdomway Pharmaceutical Co, Ltd, is subject to a reduced corporate income tax rate of **15%** in 2014 under the Western Development Strategy tax policies[216](index=216&type=chunk) [Notes to Key Items in the Consolidated Financial Statements](index=62&type=section&id=9.4%20Notes%20to%20Key%20Items%20in%20the%20Consolidated%20Financial%20Statements) This section provides detailed notes on key financial statement items, noting a change in consolidation scope due to a new subsidiary and explaining significant fluctuations in various accounts - The scope of consolidation changed during the period with the addition of one new entity, the wholly-owned subsidiary 'Xiamen Kingdomway Health Food Co, Ltd,' established on **June 9, 2014**[220](index=220&type=chunk) Explanation of Significant Fluctuations in Key Financial Statement Items | Statement Item | Fluctuation (%) | Reason for Change | | :--- | :--- | :--- | | Prepayments | 85.73% | Increase in advance payments for construction projects | | Fixed Assets | 54.43% | Transfer from projects funded by raised and excess capital | | Construction in Progress | -96.18% | Completion and transfer of projects funded by raised and excess capital | | Advances from Customers | 68.69% | Increase in advance payments received for goods | | Employee Benefits Payable | -50.14% | Payment of prior year's accrued wages and bonuses | | Taxes Payable | -283.77% | Increase in input VAT credits carried forward at period-end | [List of Reference Documents](index=103&type=section&id=Section%2010%20List%20of%20Reference%20Documents) [Reference Documents](index=103&type=section&id=10.1%20Reference%20Documents) This section lists the reference documents available for investor inspection, including signed reports and financial statements, which are kept at the company's securities affairs department

Financial Performance - The company's revenue for Q1 2014 was CNY 193,096,099.73, representing a 20.76% increase compared to CNY 159,905,648.94 in the same period last year[4] - Net profit attributable to shareholders was CNY 44,339,200.20, a significant increase of 157.51% from CNY 17,218,178.20 year-on-year[4] - Basic earnings per share rose to CNY 0.25, reflecting a 150.00% increase compared to CNY 0.10 in the previous year[4] - Operating profit increased by 151.90% due to an increase in gross sales profit[18] - The net profit attributable to the parent company increased by 157.51% mainly due to the increase in total profit[18] - The net profit attributable to shareholders for the first half of 2014 is expected to increase by 150% to 200%, amounting to between 9,098.56 and 10,918.27 thousand yuan, compared to 3,639.42 thousand yuan in the same period of 2013[20] Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,462,054,500.45, up 3.74% from CNY 1,409,323,255.53 at the end of the previous year[4] - Fixed assets increased by 49.42% due to the completion of the DHA and ARA projects, which were transferred from construction in progress[14] - Other non-current liabilities increased by 121.59% year-on-year due to government subsidies related to assets[18] Cash Flow - The net cash flow from operating activities decreased by 48.60% to CNY 10,301,206.76 from CNY 20,042,727.57 in the same period last year[4] - Cash received from other operating activities decreased by 58.17% year-on-year due to a reduction in interest income[18] Shareholder Information - The number of shareholders at the end of the reporting period was 5,964, with the top ten shareholders holding significant stakes[8] - The company plans to maintain a cash dividend distribution of no less than 10% of the distributable profit for each year during the 2012-2014 period[19] Expenses and Income - The company experienced a 56.59% year-on-year increase in selling expenses, attributed to higher transportation, consulting, and insurance costs[18] - The asset impairment loss increased by 133.65% year-on-year due to the provision for bad debts[18] - The company received tax refunds that increased by 140.41% year-on-year, primarily from export tax rebates[18] - Investment income of 271.94 thousand yuan was generated from bank principal-protected financial products, with no income reported in the same period last year[18] Advance Receipts and Fundraising - The company reported a 141.18% increase in advance receipts, attributed to received prepayments for goods[14] - The company has terminated certain fundraising investment projects related to DHA and ARA, adjusting the total investment amounts to CNY 75,005,000 and CNY 85,002,200 respectively[15] Return on Equity - The weighted average return on equity increased to 3.31%, up from 1.35% in the previous year[4]

Dividend and Capital Management - The company plans to distribute a cash dividend of 5.00 CNY per 10 shares (including tax) to all shareholders based on the total share capital as of December 31, 2013[4]. - The company will increase its capital reserve by converting 6 shares for every 10 shares held by shareholders[4]. - The company plans to increase its total share capital from 180 million to 288 million shares through a capital reserve transfer of 6 shares for every 10 shares held[101]. - The cash dividend for 2013 is proposed at 90 million RMB, which represents 88.12% of the net profit attributable to shareholders[100]. - The company has maintained a stable cash dividend policy since its listing, with an average cash dividend payout ratio of 37.70% over the past three years[97]. Financial Performance - The company's total revenue for 2013 was ¥670,158,447.13, a decrease of 0.86% compared to the previous year[25]. - Net profit attributable to shareholders was ¥102,130,623.36, reflecting a growth of 0.43% year-over-year[25]. - The operating cash flow increased significantly by 66.61%, reaching ¥201,956,793.07[25]. - The total assets at the end of 2013 were ¥1,409,323,255.53, an increase of 4.40% from the previous year[25]. - The company reported a total of 53,415.10 million RMB in raised funds, with 43,712.37 million RMB already utilized[71]. Revenue and Sales Analysis - Sales volume of coenzyme Q10 products grew by 37.08%, with production costs decreasing by 5.8% and average prices increasing by 4.29%[25]. - Vitamin A sales volume declined by 5.32% and Vitamin D3 sales volume decreased by 30.33%, with average prices dropping by 4.96% and 43.89% respectively[25]. - The revenue from Coenzyme Q10 series increased by 42.95% to ¥366,711,371.38, driven by a 37.08% increase in sales volume and a 4.29% increase in average selling price[34]. - Vitamin D3 series revenue decreased by 60.91% to ¥35,264,026.72, attributed to a 30.33% drop in sales volume and a 43.89% decline in average selling price[34]. - The company's total sales revenue from goods and services received cash of ¥705,817,342.43, up from ¥648,200,222.29, representing an increase of approximately 8.5%[196]. Research and Development - The company invested ¥39,982,500 in R&D, conducting 32 research projects, with several achieving industrial application[29]. - R&D expenditure increased by 16.50% to CNY 39,982,503.28, accounting for 5.97% of operating revenue[47]. - The company is committed to innovation in the nutritional fortifier and biopharmaceutical sectors, focusing on diversification and the development of new products[88]. Risk Management - The company acknowledges risks related to product market development, exchange rate fluctuations, environmental protection, and litigation that may impact profitability[11]. - The company emphasizes the importance of risk awareness for investors regarding forward-looking statements in its reports[4]. - The company faces risks related to exchange rate fluctuations, as over 60% of its products are exported[90]. - The ongoing litigation regarding the Kaneka patent may introduce uncertainties that could affect the company's performance[91]. Environmental and Social Responsibility - The company allocated over ¥2,400,000 for environmental improvement projects, enhancing its environmental quality and corporate image[28]. - The company actively engages in environmental protection and has integrated energy conservation and emission reduction into its key agenda[105]. - The company is not classified as a heavily polluting industry by national environmental protection authorities[106]. - The company has been recognized as a trustworthy enterprise in contract performance for the years 2012-2013 in Xiamen[104]. Corporate Governance and Management - The company has established a comprehensive supplier evaluation mechanism and quality management system to ensure product quality and safety[104]. - The company has maintained compliance with corporate governance regulations and has not received any administrative regulatory measures from supervisory authorities[152]. - The independent directors attended board meetings and shareholder meetings, with no objections raised against company matters during the reporting period[156]. - The company has a management reward scheme based on operational performance and individual performance, approved by the shareholders' meeting[143]. Shareholder Information - The total number of shareholders at the end of the reporting period was 8,653, compared to 5,669 five trading days before the annual report disclosure[126]. - The largest shareholder, Xiamen Jindawei Investment Co., Ltd., holds 35.00% of shares, totaling 63,003,304 shares, with 43,000,000 shares pledged[126]. - The second largest shareholder, Zhongmu Industrial Co., Ltd., holds 26.47% of shares, totaling 47,644,120 shares, with no shares pledged[126]. - The company has not proposed or implemented any share increase plans during the reporting period[132]. Employee and Workforce - The total number of employees as of December 31, 2013, is 1,392[147]. - The employee distribution by professional structure includes 1,006 production personnel, 179 technical personnel, and 88 management personnel[147]. - The educational background of employees shows 194 with a bachelor's degree or above, 243 with a college diploma, and 709 with high school or vocational education[149]. Financial Audit and Compliance - The company received a standard unqualified audit opinion from the auditing firm, confirming the accuracy of its financial statements[173]. - The audit committee held five meetings during the reporting period to review quarterly financial statements and internal audit reports, ensuring compliance with regulations and maintaining audit independence[157]. - The company has not experienced any significant accounting errors or changes in accounting policies compared to the previous year[93][94].